Switch theme
Sign up to access all valuation multiples
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (34%), and life sciences (14%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.
1904
11.8K+
LTM Revenue $3.6B
LTM EBITDA $695M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Getinge has a last 12-month revenue (LTM) of $3.6B and a last 12-month EBITDA of $695M.
In the most recent fiscal year, Getinge achieved revenue of $3.6B and an EBITDA of $548M.
Getinge expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Getinge valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| Gross Profit | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $695M | XXX | $548M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $353M | XXX | $381M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $212M | XXX | $169M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $615M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Getinge's stock price is SEK 185 (or $19).
Getinge has current market cap of SEK 50.4B (or $5.2B), and EV of SEK 57.7B (or $5.9B).
See Getinge trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $5.2B | XXX | XXX | XXX | XXX | $1.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Getinge has market cap of $5.2B and EV of $5.9B.
Getinge's trades at 1.7x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate Getinge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Getinge has a P/E ratio of 24.6x.
See valuation multiples for Getinge and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 16.9x | XXX | 15.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.6x | XXX | 30.8x | XXX | XXX | XXX |
| EV/FCF | 47.2x | XXX | 17.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGetinge's last 12 month revenue growth is 3%
Getinge's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Getinge's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Getinge's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Getinge and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Getinge acquired XXX companies to date.
Last acquisition by Getinge was XXXXXXXX, XXXXX XXXXX XXXXXX . Getinge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Getinge founded? | Getinge was founded in 1904. |
| Where is Getinge headquartered? | Getinge is headquartered in Sweden. |
| How many employees does Getinge have? | As of today, Getinge has 11.8K+ employees. |
| Who is the CEO of Getinge? | Getinge's CEO is Mr. Mattias Perjos. |
| Is Getinge publicy listed? | Yes, Getinge is a public company listed on STO. |
| What is the stock symbol of Getinge? | Getinge trades under GETI B ticker. |
| When did Getinge go public? | Getinge went public in 1998. |
| Who are competitors of Getinge? | Similar companies to Getinge include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Getinge? | Getinge's current market cap is $5.2B |
| What is the current revenue of Getinge? | Getinge's last 12 months revenue is $3.6B. |
| What is the current revenue growth of Getinge? | Getinge revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Getinge? | Current revenue multiple of Getinge is 1.6x. |
| Is Getinge profitable? | Yes, Getinge is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Getinge? | Getinge's last 12 months EBITDA is $695M. |
| What is Getinge's EBITDA margin? | Getinge's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Getinge? | Current EBITDA multiple of Getinge is 8.6x. |
| What is the current FCF of Getinge? | Getinge's last 12 months FCF is $126M. |
| What is Getinge's FCF margin? | Getinge's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Getinge? | Current FCF multiple of Getinge is 47.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
